Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition

Abstract excerpt

The synthetic lethal effect observed with the use of PARP inhibitors (PARPi) with tumors characterized by the loss of key players in the homologous recombination (HR) pathway, commonly referred to as "BRCAness", is maintaining high interest in oncology. While BRCAness is a well-established feature in breast, ovarian, prostate, and pancreatic carcinomas, our recent findings indicate that up to 15% of colorectal...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy
• Share to Toxin Mechanisms and Immunotoxins